ASX:TLXBiotechs
How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) 2026 Guidance, Shelf Filing And Glioma Push
In February 2026, Telix Pharmaceuticals reported full-year 2025 sales of US$803.79 million alongside a small net loss of US$7.13 million, issued group revenue guidance of US$950 million to US$970 million for 2026, filed a shelf registration for its American Depositary Shares, and submitted a European marketing authorization application for its glioma imaging candidate TLX101-Px.
A key implication of these updates is that Telix is coupling higher revenue ambitions and potential...